Albany Molecular Research, Inc.  

(Public, NASDAQ:AMRI)   Watch this stock  
Find more results for AMRI
+0.23 (1.78%)
Real-time:   11:05AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 13.00 - 13.44
52 week 12.45 - 22.48
Open 13.07
Vol / Avg. 27,546.00/260,155.00
Mkt cap 484.85M
P/E     -
Div/yield     -
EPS -0.29
Shares 35.70M
Beta 1.59
Inst. own 88%
Aug 2, 2016
Q2 2016 Albany Molecular Research Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 7, 2016
Albany Molecular Research Inc at Jefferies Healthcare Conference
Jun 2, 2016
Albany Molecular Research Inc Annual Shareholders Meeting (Estimated)
Jun 1, 2016
Albany Molecular Research Inc Annual Shareholders Meeting
May 10, 2016
Q1 2016 Albany Molecular Research Inc Earnings Release
May 10, 2016
Q1 2016 Albany Molecular Research Inc Earnings Call - Webcast
May 5, 2016
Albany Molecular Research Inc Conference call to Discuss the Definitive Agreement to Acquire Euticals
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -9.54% -0.57%
Operating margin -3.93% 3.39%
EBITD margin - 12.54%
Return on average assets -4.75% -0.33%
Return on average equity -14.07% -0.87%
Employees 2,220 -
CDP Score - -


21 Corporate Cir, PO Box 15098
ALBANY, NY 12203-5154
United States - Map
+1-518-4640279 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Albany Molecular Research, Inc. is a global contract research and manufacturing company. The Company provides drug discovery, development, and manufacturing services. The Company operates through three segments: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM). The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small-scale commercial manufacturing. API includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates and high potency and controlled substance manufacturing. DPM includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized injectable formulations. It supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs.

Officers and directors

William S. Marth President, Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Felicia Ladin Chief Financial Officer, Senior Vice President, Treasurer
Age: 43
Bio & Compensation  - Reuters
Lori M. Henderson Esq. Senior Vice President, General Counsel, Secretary
Age: 53
Bio & Compensation  - Reuters
Christopher Conway Senior Vice President - Discovery and Development and Global Commercial Sales
Bio & Compensation  - Reuters
Milton Boyer Senior Vice President - Drug Product Manufacturing
Bio & Compensation  - Reuters
Steven R. Hagen Ph.D. Senior Vice President - Manufacturing and Pharmaceuticals
Age: 54
Bio & Compensation  - Reuters
George Svokos Chief Commercial Officer and Senior Vice President, API
Age: 57
Bio & Compensation  - Reuters
Jimmy Wang Ph.D. Chief Information Officer
Bio & Compensation  - Reuters
Thomas E. D' Ambra Ph.D. Non-Executive Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Una S. Ryan Ph.D., OBE Lead Independent Director
Age: 73
Bio & Compensation  - Reuters